CA2253342A1 - Biphenylsulfonamide matrix metalloproteinase inhibitors - Google Patents
Biphenylsulfonamide matrix metalloproteinase inhibitors Download PDFInfo
- Publication number
- CA2253342A1 CA2253342A1 CA002253342A CA2253342A CA2253342A1 CA 2253342 A1 CA2253342 A1 CA 2253342A1 CA 002253342 A CA002253342 A CA 002253342A CA 2253342 A CA2253342 A CA 2253342A CA 2253342 A1 CA2253342 A1 CA 2253342A1
- Authority
- CA
- Canada
- Prior art keywords
- biphenyl
- sulfonylamino
- methyl
- butyric acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1746096P | 1996-05-17 | 1996-05-17 | |
| US60/017,460 | 1996-05-17 | ||
| PCT/US1997/006801 WO1997044315A1 (en) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2253342A1 true CA2253342A1 (en) | 1997-11-27 |
Family
ID=21782716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002253342A Abandoned CA2253342A1 (en) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0901466B1 (enExample) |
| JP (1) | JP2000511175A (enExample) |
| KR (1) | KR20000011095A (enExample) |
| CN (1) | CN1077885C (enExample) |
| AT (1) | ATE207891T1 (enExample) |
| BG (1) | BG63940B1 (enExample) |
| BR (1) | BR9710841A (enExample) |
| CA (1) | CA2253342A1 (enExample) |
| CZ (1) | CZ294063B6 (enExample) |
| DE (1) | DE69707865T2 (enExample) |
| DK (1) | DK0901466T3 (enExample) |
| EA (1) | EA001561B1 (enExample) |
| EE (1) | EE03965B1 (enExample) |
| ES (1) | ES2167733T3 (enExample) |
| IL (1) | IL126832A0 (enExample) |
| NO (1) | NO312510B1 (enExample) |
| NZ (1) | NZ332711A (enExample) |
| PL (1) | PL186416B1 (enExample) |
| PT (1) | PT901466E (enExample) |
| SK (1) | SK282863B6 (enExample) |
| WO (1) | WO1997044315A1 (enExample) |
| ZA (1) | ZA974223B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2193692A1 (en) * | 1994-06-22 | 1995-12-28 | Andrew Miller | Metalloproteinase inhibitors |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| EP1366765A1 (en) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| DK0946166T3 (da) * | 1996-12-17 | 2004-05-03 | Warner Lambert Co | Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| EP1029541B1 (en) * | 1997-07-22 | 2006-03-22 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
| KR20010033473A (ko) * | 1997-12-23 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제 |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| CN1195735C (zh) * | 1998-02-04 | 2005-04-06 | 诺瓦提斯公司 | 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物 |
| BR9815745A (pt) * | 1998-03-17 | 2000-11-14 | Warner Lambert Co | Combinações de inibidor de metaloproteinase de matriz estatina |
| EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
| JP4567886B2 (ja) * | 1998-07-16 | 2010-10-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 医薬として使用されるホスフィン酸およびホスホン酸誘導体 |
| AU4701799A (en) * | 1998-07-21 | 2000-02-14 | Warner-Lambert Company | Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions |
| DE19851184A1 (de) * | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6495578B1 (en) * | 1999-04-19 | 2002-12-17 | Shionogi & Co., Ltd. | Sulfonamide derivatives having oxadiazole rings |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| EP2014285B1 (en) | 1999-11-26 | 2010-05-05 | Shionogi&Co., Ltd. | NPYY5 antagonists |
| KR20030030036A (ko) * | 2000-09-29 | 2003-04-16 | 시오노기세이야쿠가부시키가이샤 | 티아졸 또는 옥사졸 유도체 |
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| MXPA01013326A (es) * | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| WO2003035610A1 (en) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Sulfonamide derivative having mmp inhibitory activity |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP2007525406A (ja) * | 2003-12-04 | 2007-09-06 | ワイス | ビアリールスルホンアミドおよびその使用方法 |
| NZ550621A (en) | 2004-03-22 | 2009-11-27 | Southern Res Inst | Nonpeptide inhibitors of matrix metalloproteinases |
| CN101279956B (zh) * | 2008-04-25 | 2011-06-15 | 南昌大学 | 一种基质金属蛋白酶抑制剂及合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| CA2193692A1 (en) * | 1994-06-22 | 1995-12-28 | Andrew Miller | Metalloproteinase inhibitors |
-
1997
- 1997-04-24 KR KR1019980709253A patent/KR20000011095A/ko not_active Ceased
- 1997-04-24 SK SK1577-98A patent/SK282863B6/sk unknown
- 1997-04-24 CZ CZ19983668A patent/CZ294063B6/cs not_active IP Right Cessation
- 1997-04-24 IL IL12683297A patent/IL126832A0/xx unknown
- 1997-04-24 AT AT97918788T patent/ATE207891T1/de not_active IP Right Cessation
- 1997-04-24 EP EP97918788A patent/EP0901466B1/en not_active Expired - Lifetime
- 1997-04-24 DE DE69707865T patent/DE69707865T2/de not_active Expired - Fee Related
- 1997-04-24 EE EE9800397A patent/EE03965B1/xx not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006801 patent/WO1997044315A1/en not_active Ceased
- 1997-04-24 DK DK97918788T patent/DK0901466T3/da active
- 1997-04-24 EA EA199800988A patent/EA001561B1/ru not_active IP Right Cessation
- 1997-04-24 PL PL97329929A patent/PL186416B1/pl not_active IP Right Cessation
- 1997-04-24 PT PT97918788T patent/PT901466E/pt unknown
- 1997-04-24 CA CA002253342A patent/CA2253342A1/en not_active Abandoned
- 1997-04-24 NZ NZ332711A patent/NZ332711A/en unknown
- 1997-04-24 BR BR9710841A patent/BR9710841A/pt not_active IP Right Cessation
- 1997-04-24 ES ES97918788T patent/ES2167733T3/es not_active Expired - Lifetime
- 1997-04-24 CN CN97194719A patent/CN1077885C/zh not_active Expired - Fee Related
- 1997-04-24 JP JP09542377A patent/JP2000511175A/ja not_active Abandoned
- 1997-05-15 ZA ZA9704223A patent/ZA974223B/xx unknown
-
1998
- 1998-11-12 BG BG102918A patent/BG63940B1/bg unknown
- 1998-11-16 NO NO19985326A patent/NO312510B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO985326L (no) | 1999-01-14 |
| BR9710841A (pt) | 1999-08-17 |
| PL186416B1 (pl) | 2004-01-30 |
| SK282863B6 (sk) | 2002-12-03 |
| HK1019585A1 (en) | 2000-02-18 |
| EA199800988A1 (ru) | 1999-04-29 |
| EE03965B1 (et) | 2003-02-17 |
| KR20000011095A (ko) | 2000-02-25 |
| PL329929A1 (en) | 1999-04-26 |
| ZA974223B (en) | 1997-12-10 |
| EA001561B1 (ru) | 2001-04-23 |
| ATE207891T1 (de) | 2001-11-15 |
| DK0901466T3 (da) | 2002-02-18 |
| DE69707865T2 (de) | 2002-05-02 |
| BG63940B1 (bg) | 2003-07-31 |
| EE9800397A (et) | 1999-06-15 |
| AU2680397A (en) | 1997-12-09 |
| NO312510B1 (no) | 2002-05-21 |
| PT901466E (pt) | 2002-04-29 |
| AU713286B2 (en) | 1999-11-25 |
| CZ366898A3 (cs) | 1999-02-17 |
| NZ332711A (en) | 2000-06-23 |
| CZ294063B6 (cs) | 2004-09-15 |
| CN1077885C (zh) | 2002-01-16 |
| EP0901466B1 (en) | 2001-10-31 |
| WO1997044315A1 (en) | 1997-11-27 |
| NO985326D0 (no) | 1998-11-16 |
| JP2000511175A (ja) | 2000-08-29 |
| CN1219166A (zh) | 1999-06-09 |
| BG102918A (en) | 1999-09-30 |
| EP0901466A1 (en) | 1999-03-17 |
| DE69707865D1 (de) | 2001-12-06 |
| SK157798A3 (en) | 1999-04-13 |
| ES2167733T3 (es) | 2002-05-16 |
| IL126832A0 (en) | 1999-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0901466B1 (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors | |
| US5756545A (en) | Biphenysulfonamide matrix metal alloproteinase inhibitors | |
| EP0934267B1 (en) | Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors | |
| JP5450105B2 (ja) | ビフェニル−４−イル−スルホン酸アリールアミド及びその治療剤としての使用 | |
| KR19980086847A (ko) | 설포닐아미노카복실산 | |
| EP0214639A2 (en) | Hydroxamic acid based collagenase inhibitors | |
| KR20000070233A (ko) | Ｍｍｐ 억제제로서 비스-술폰아미드 히드록삼산 | |
| ES2277424T3 (es) | Derivados de n- hidroxiformamida. | |
| CS271469B2 (en) | Method of phenoxyalkylcarboxyl acid's derivatives production | |
| CN101568521A (zh) | 硫代芳基取代的锌蛋白酶抑制剂和它们的用途 | |
| EP0923569B1 (en) | Butyric acid matrix metalloproteinase inhibitors | |
| AU713286C (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors | |
| EP0341081A2 (en) | Novel amino acid derivatives | |
| CA2133115A1 (en) | Carboxylate derivatives exhibiting phospholipase a2 inhibitory activity | |
| MXPA98009083A (en) | Metaloproteinase inhibitors with bifenilsulfonam matrix | |
| JP2000508639A (ja) | Ｍｍｐおよびｔｎｆ抑制活性を有するペプチジル化合物 | |
| PT99572A (pt) | Processo para a preparacao de novas sulfonamidas e de composicoes farmaceuticas que as contem | |
| EP0375557A1 (en) | Glycine derivative process for preparation thereof, and pharmaceutical composition containing it | |
| HK1019585B (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |